CCM
BCAX

Catalio Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Catalio Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-97,800
Closed -$909K – 49
2025
Q2 		$909K Buy
+97,800
New +$1.17M 0.19% 33

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Catalio Capital Management's BCAX Position: Q3 2025 in Review

Catalio Capital Management sold out of Bicara Therapeutics (BCAX) in Q3 2025, closing a stake of 97,800 shares — an estimated $909K sold.

Catalio Capital Management first reported a position in BCAX in Q2 2025 and held it in 1 quarter. The position peaked at $909K in Q2 2025. 114 funds tracked by Wall St. Rank hold BCAX as of Q3 2025.

  • Catalio Capital Management reported no remaining Bicara Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Catalio Capital Management sold 97,800 Bicara Therapeutics shares in Q3 2025, an estimated $909K.
  • Catalio Capital Management first reported a position in Bicara Therapeutics in Q2 2025 and held it in 1 quarter.
  • Catalio Capital Management's Bicara Therapeutics position peaked at $909K in Q2 2025.
  • 114 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2025.

Based on Catalio Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.